Cayetano Heredia University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lima Peru (1961)

Organization Overview

First Clinical Trial
2004
NCT00111514
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Department of Microbiology, Universidad Peruana Cayetano Heredia | Hospital Nacional Cayetano Heredia | Universidad Peruana Cayetano Heredia | Universidad Peruana Cayetano Heredia, Lima, Peru | Universidad Peruana Cayetano Heredia (UPCH) | University Cayetano Heredia, Lima, Peru

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Altitude Sickness (Phase 4)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 2)

Cysticercosis (Phase 3)

Epilepsy (Phase 3)

Helminthiasis (Phase 2)

HTLV-I Infections (Phase 1)

Hypoventilation (Phase 4)

Infarction (Phase 3)

Infections (Phase 4)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Leishmaniasis, Mucocutaneous (Phase 1)

Muscle Spasticity (Phase 1)

Myocardial Infarction (Phase 3)

Neonatal Sepsis (Phase 3)

Neurocysticercosis (Phase 3)

Papillomavirus Infections (Phase 4)

Paraparesis (Phase 1)

Paraparesis, Spastic (Phase 1)

Paraparesis, Tropical Spastic (Phase 1)

Polycythemia (Phase 4)

Prostatic Neoplasms (Phase 3)

Seizures (Phase 3)

Sepsis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

ST Elevation Myocardial Infarction (Phase 3)

Surgical Wound Infection (Phase 3)

Taeniasis (Phase 3)

Toxemia (Phase 3)

Trichuriasis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial APIs: 32